摘要
目的:探讨地氯雷他定联合疏风脱敏汤对过敏性皮炎症状消失时间、疗效的影响。方法:选取2020年3月—2021年3月我院确诊的过敏性皮炎患者86例,按照随机数字表法分为对照组和观察组,每组43例。对照组采用地氯雷他定治疗,观察组在对照组基础上联合疏风脱敏汤治疗,比较两组临床疗效、症状消失时间、不良反应发生率以及不同治疗阶段的血清学指标水平。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。观察组瘙痒、皮疹及红肿症状消失时间均短于对照组,差异有统计学意义(P<0.05)。治疗后2、4周,观察组血清白介素-18(IL-18)水平高于对照组,EB病毒(EBV)抗体水平低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:地氯雷他定与疏风脱敏汤联用能够促进过敏性皮炎症状消失,提升临床疗效,并保障用药安全性,或与其能够下调血清EBV抗体水平、增强IL-18表达有关。
Objective: To investigate the effect of desloratadine combined with Shufeng desensitization decoction on the disappearance time and efficacy of atopic dermatitis. Methods: A total of 86 patients with atopic dermatitis diagnosed in our hospital from March 2020 to March 2021 were selected and divided into control group and observation group according to random number table method, with 43 cases in each group. The control group was treated with desloratadine, and the observation group was treated with shufeng desensitization decoction on the basis of the control group. The clinical efficacy, symptom disappearance time, incidence of adverse reactions and the level of serological indicators in different treatment stages were compared between the two groups. Results: The total effective rate of observation group was higher than control group, the difference was statistically significant(P<0.05). The time to disappear of pruritus, rash and redness was shorter in the observation group than in the control group, and the difference was statistically significant(P<0.05). At 2 and 4 weeks after treatment, the level of serum interleukin-18(IL-18) in the observation group was higher than that in the control group, and the level of EB virus(EBV) antibody was lower than that in the control group, the differences were statistically significant(P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P >0.05). Conclusion: Desloratadine combined with shufeng desensitization decoction can promote the disappearance of atopic dermatitis symptoms, improve clinical efficacy, and ensure drug safety, which may be related to its ability to downregulate serum EBV antibody level and enhance il-18 expression.
作者
李银玲
表贞淑
LI Yinling;BIAO Zhenshu(Department of Dermatology,Liaoning Provincial People’s Hospital,Shenyang 110016,Liaoning,China)
出处
《中国药物滥用防治杂志》
CAS
2021年第5期760-762,770,共4页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
过敏性皮炎
地氯雷他定
疏风脱敏汤
血清学指标
allergic dermatitis
Desloratadine
Shufeng desensitization soup
Serological indicators
